High-throughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV-1 inhibitors in a cell-based assay

Antiviral Research

Volumn 81, Issue 3, 2009, Pages 239-247

  Garcia, Jean Michel ^a   Gao, Anhui ^b   He, Pei Lan ^b   Choi, Joyce ^a   Tang, Wei ^b   Bruzzone, Roberto ^a   Schwartz, Olivier ^c   Naya, Hugo ^d   Nan, Fa Jun ^b   Li, Jia ^b   Altmeyer, Ralf ^a   Zuo, Jian Ping ^b  

^a HKU PASTEUR RESEARCH CENTRE   (Hong Kong)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c INSTITUT PASTEUR   (France)

^d INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

Author keywords

Cocktail library; High throughput screening; HIV; HTS; NNRTI; Pseudotyped lentiviral particles

Indexed keywords

LAMIVUDINE; NC 80937; NC 83040; NC 85497; NC 86077; NC 87463; NC 88104; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANALYTIC METHOD; ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CHINESE MEDICINE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LENTIVIRINAE; PRIORITY JOURNAL; PSEUDOTYPING; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 60249084658     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.12.004     Document Type: Article

References (49)

1. Baum C., Schambach A., Bohne J., and Galla M. Retrovirus vectors: toward the plentivirus?. Mol. Ther. 13 (2006) 1050-1063
2. Bennasser Y., Yeung M.L., and Jeang K.T. RNAi therapy for HIV infection: principles and practicalities. BioDrugs 21 (2007) 17-22
3. Bukreyev A., Skiadopoulos M.H., Murphy B.R., and Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 80 (2006) 10293-10306
4. Burns J.C., Friedmann T., Driever W., Burrascano M., and Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8033-8037
5. Cao Y.L., and Guo Y. Screening of HIV-1 replication inhibitors by using pseudotyped virus system. Yao Xue Xue Bao 43 (2008) 253-258
6. Chan E., Heilek-Snyder G., Cammack N., Sankuratri S., and Ji C. Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors. J. Biomol. Screen. 11 (2006) 652-663
7. Chan S.Y., Empig C.J., Welte F.J., Speck R.F., Schmaljohn A., Kreisberg J.F., and Goldsmith M.A. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106 (2001) 117-126
8. Clavel F., and Charneau P. Fusion from without directed by human immunodeficiency virus particles. J. Virol. 68 (1994) 1179-1185
9. Cohen J. Did Merck's failed HIV vaccine cause harm?. Science 318 (2007) 1048-1049
10. Cohen J. Promising AIDS vaccine's failure leaves field reeling. Science 318 (2007) 28-29
11. Codran A., Royer C., Jaeck D., Bastien-Valle M., Baumert T.F., Kieny M.P., Pereira C.A., and Martin J.P. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J. Gen. Virol. 87 (2006) 2583-2593
12. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 (1995) 935-944
13. De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med. Res. Rev. 20 (2000) 323-349
14. de la Carrière L.C., Paulous S., Clavel F., and Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J. Virol. 73 (1999) 3455-3459
15. Esté J.A., and Telenti A. HIV entry inhibitors. Lancet 370 (2007) 81-88
16. Eustice D.C., Feldman P.A., Colberg-Poley A.M., Buckery R.M., and Neubauer R.H. A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques 11 (1991) 739-740 and 742-743
17. Faustino R.S., Nelson T.J., Terzic A., and Perez-Terzic C. Nuclear transport: target for therapy. Clin. Pharmacol. Ther. 81 (2007) 880-886
18. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6 (2007) 959-966
19. Fukushi S., Mizutani T., Saijo M., Kurane I., Taguchi F., Tashiro M., and Morikawa S. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody response to SARS-CoV. J. Med. Virol. 78 (2006) 1509-1512
20. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T., Sugimoto H., Endo T., Murai H., and Davies D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13040-13043
21. Kim S.H., Kim S., and Robbins P.D. Retroviral vectors. Adv. Virus Res. 55 (2000) 545-563
22. Liu Y., Murakami N., Zhang S., and Xu T. Structure-activity relationships of 1′-acetoxychavicol acetate homologues as new nuclear export signal inhibitors. Pharmazie 62 (2007) 659-662
23. Lundholt B.K., Scudder K.M., and Pagliaro L. A simple technique for reducing edge effect in cell-based assays. J. Biomol. Screen. 8 (2003) 566-570
24. Ma M., Kersten D.B., Kamrud K.I., Wool-Lewis R.J., Schmaljohn C., and González-Scarano F. Murine leukemia virus pseudotypes of La Crosse and Hantaan bunyaviruses: a system for analysis of cell tropism. Virus Res. 64 (1999) 23-32
25. Maréchal V., Clavel F., Heard J.M., and Schwartz O. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J. Virol. 72 (1998) 2208-2212
26. Mastromarino P., Conti C., Goldoni P., Hauttecoeur B., and Orsi N. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol. 68 (1987) 2359-2369
27. Morizono K., and Harada S. Human immunodeficiency virus type 1 (HIV-1) infection and transcytosis activity of a HIV-1 susceptible clone from HeLa cell. Microbiol. Immunol. 42 (1998) 313-320
28. Moore J.P., Kitchen S.G., Pugach P., and Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20 (2004) 111-126
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
30. Muraglia E., Kinzel O.D., Laufer R., Miller M.D., Moyer G., Munshi V., Orvieto F., Palumbi M.C., Pescatore G., Rowley M., Williams P.D., and Summa V. Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg. Med. Chem. Lett. 16 (2006) 2748-2752
31. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
32. Nefkens I., Garcia J.-M., Ling C.S., Lagarde N., Nicholls J., Tang D.J., Peiris M., Buchy P., and Altmeyer R. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol. 39 (2007) 27-33
33. Noah J.W., Severson W., Noah D.L., Rasmussen L., White E.L., and Jonsson C.B. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73 (2007) 50-59
34. Olesen C.E., Yan Y.X., Liu B., Martin D., D'Eon B., Judware R., Martin C., Voyta J.C., and Bronstein I. Novel methods for chemiluminescent detection of reporter enzymes. Methods Enzymol. 326 (2000) 175-202
35. Petit C., Buseyne F., Boccaccio C., Abastado J.P., Heard J.M., and Schwartz O. Nef is required for efficient HIV-1 replication in cocultures of dendritic cells and lymphocytes. Virology 286 (2001) 225-236
36. Pillay D., Taylor S., and Richman D.D. Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10 (2000) 231-253
37. Ritz, C., Streibig, J.C., 2005. Bioassay Analysis using R.J. Statist Software, vol. 12, issue 5.
38. Salzwedel K., Martin D.E., and Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 9 (2007) 162-172
39. Schwartz O., Maréchal V., Danos O., and Heard J.M. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69 (1995) 4053-4059
40. Sension M.G. Long-term suppression of HIV infection: benefits and limitations of current treatment options. J. Assoc. Nurses AIDS Care 18 (2007) S2-10
41. Sol-Foulon N., Sourisseau M., Porrot F., Thoulouze M.I., Trouillet C., Nobile C., Blanchet F., di Bartolo V., Noraz N., Taylor N., Alcover A., Hivroz C., and Schwartz O. ZAP-70 kinase regulates HIV cell-to-cell spread and virological synapse formation. EMBO J. 26 (2007) 516-526
42. Soriano V., and de Mendoza C. Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clin. Trials 3 (2002) 237-248
43. Sorin M., and Kalpana G.V. Dynamics of virus-host interplay in HIV-1 replication. Curr. HIV Res. 4 (2006) 117-130
44. UNAIDS/WHO, 2007. AIDS Epidemic Update, December 2007, Geneva.
45. Watanabe N., Yamaguchi T., Akimoto Y., Rattner J.B., Hirano H., and Nakauchi H. Induction of M-phase arrest and apoptosis after HIV-1 Vpr expression through uncoupling of nuclear and centrosomal cycle in HeLa cells. Exp. Cell Res. 258 (2000) 261-269
46. Wool-Lewis R.J., and Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72 (1998) 3155-3160
47. Yeni P. Update on HAART in HIV. J. Hepatol. 44 (2006) S100-103
48. Zeinalipour-Loizidou E., Nicolaou C., Nicolaides A., and Kostrikis L.G. HIV-1 integrase: from biology to chemotherapeutics. Curr. HIV Res. 5 (2007) 365-388
49. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73